On the 29th, the state organized joint drug procurement office issued an announcement on canceling the qualification of glimepiride tablets of Guizhou Guizhou Salvage Pharmaceutical Co.Ltd(600227) Pharmaceutical Co., Ltd. and listing the enterprise in the list of violations.
The announcement proposed that the glimepiride tablets produced by Guizhou Guizhou Salvage Pharmaceutical Co.Ltd(600227) Pharmaceutical Co., Ltd., the second batch of drugs purchased by the state, did not meet the drug production quality management standards.
When answering reporters’ questions on relevant matters, the person in charge of the state organization drug joint procurement office said that according to the information publicly released by Guizhou Provincial Drug Administration, the flight inspection found that Guizhou Salvage Pharmaceutical Co.Ltd(600227) pharmaceutical had serious defects in plant maintenance, equipment cleaning and stability inspection, which did not comply with the norms of drug production quality management. The production and sales of glimepiride tablets of the enterprise were suspended according to law, and further investigation and treatment were conducted.
The official said that the selection results of Guizhou Salvage Pharmaceutical Co.Ltd(600227) pharmaceutical glimepiride tablets will be implemented from April 2020. The agreement period is three years. At present, the supply agreement for the second procurement year is being implemented.
Guizhou Salvage Pharmaceutical Co.Ltd(600227) pharmaceutical is subject to regulatory measures by the drug regulatory department because it does not comply with the drug production quality management norms, violates the commitment of the enterprise to be responsible for drug quality and supply, and cannot continue to perform the contract and meet the clinical drug demand of medical institutions.
“In accordance with the spirit of the opinions of the general office of the State Council on promoting the normalization and institutionalization of centralized drug procurement (GBF [2021] No. 2) and the relevant provisions of the national document on centralized drug procurement (gy-yd2019-2), we The pharmaceutical company will be severely punished, disqualified from being selected, included in the list of violations, and suspended from January 29, 2022 to July 28, 2023 to participate in the declaration qualification of the centralized drug procurement activities organized by the state. This is the corresponding punishment for their production violations and failure to continue to perform the contract. ” The official said.
According to the announcement, the joint procurement office will start the replacement procedure of glimepiride tablets according to the relevant provisions of the national centralized drug procurement document (gy-yd2019-2), and other qualified selected enterprises will supply the original supply provinces of Guizhou Guizhou Salvage Pharmaceutical Co.Ltd(600227) Pharmaceutical Co., Ltd. to ensure the drug supply in relevant regions. The specific results will be announced separately.
